MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance
under at - the - market...
$6,833K
Proceeds from issuance
common stock and...
$6,690K
Proceeds from warrant
inducement
$3,942K
Proceeds from long term
debt
$1,507K
Tax credit
receivable
$287K
Proceeds from issuance of
common stock for...
$4K
Net cash provided by
financing activities
$18,193K
Canceled cashflow
$1,070K
Net increase
(decrease) in cash and cash...
$1,397K
Canceled cashflow
$16,796K
Payment of contingent
consideration
-$1,000K
Payment of loans payable
-$70K
Change in fair value of
contingent consideration
$9,031K
Stock-based compensation
$654K
Non - cash lease
expense
$522K
Prepaid expenses and
other current assets
-$456K
Depreciation
$108K
Accounts payable
$69K
Loss on asset
disposal
$1K
Net cash used in
operating activities
-$16,669K
Effects of exchange rate
changes on cash and cash...
-$92K
Net cash used in
investing activities
-$35K
Canceled cashflow
$10,841K
Net loss
-$23,739K
Purchases of property and
equipment
$35K
Accrued expenses
-$2,277K
Accrued employee
benefits
-$744K
Operating lease liability
-$562K
Deferred research and
development tax credit
-$188K
Back
Back
Cash Flow
source: myfinsight.com
Theriva Biologics, Inc. (TOVX)
Theriva Biologics, Inc. (TOVX)